Bluebird bio, Inc.
BLUE
Rank in Stocks
#15569
bluebird bio, Inc. is a biotechnology firm that concentrates on the discovery,... bluebird bio, Inc. is a biotechnology firm that concentrates on the discovery, development, and commercialization of innovative gene therapies. These pioneering treatments are aimed at debilitating genetic conditions. Among its leading investigational therapies for severe inherited diseases are betibeglogene autotemcel (beti-cel), intended for patients with transfusion-dependent beta-thalassemia; lovotibeglogene autotemcel (lovo-cel), which targets sickle cell disease (SCD); and elivaldogene autotemcel (eli-cel), developed to address cerebral adrenoleukodystrophy. The company's robust clinical trial program is actively evaluating the safety and efficacy of these treatments. Specifically, lovo-cel's impact on SCD patients is being assessed in studies HGB-205, HGB-206, and HGB-210. Concurrently, beti-cel is under investigation for beta-thalassemia in trials HGB-204, HGB-205, HGB-207, and HGB-212. Furthermore, bluebird bio maintains strategic collaborations and licensing arrangements with entities such as Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company, which began its operations in 1992, was formerly known as Genetix Pharmaceuticals, Inc., and rebranded as bluebird bio, Inc. in September 2010. Its principal office is located in Cambridge, Massachusetts.
Share Price
$4.97
Last synced: 2025-06-02
Market Cap
$318.62M
Change (1 day)
0.00%
Change (1 year)
-38.03%
Country
US
Trade Bluebird bio, Inc. (BLUE)
Category
Healthcare
Stock price history for Bluebird bio, Inc. (BLUE)
Highest end of day price: $8.24 on 2025-01-01
Lowest end of day price: $1.93K on 2018-01-01
Lowest end of day price: $1.93K on 2018-01-01
Stock price history of Bluebird bio, Inc. from 2018 to 2026
Annual Stock Price Performance
| Year | Performance |
|---|---|
| 2025 | -0.01% |
| 2024 | -86.21% |
| 2023 | -60.75% |
| 2022 | -23.07% |
| 2021 | -59.15% |
| 2020 | -57.22% |
| 2019 | -15.48% |
| 2018 | 0.00% |
Stock price for similar companies or competitors
| Company | Stock price | Change 1y% | Country |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $758.70 | 7.84% |
CH
|
